Results 101 to 110 of about 21,800 (268)

Lymphocyte subsets in the peripheral blood of donors and into the collected bags in the platelet and the granulocyte apheresis using the IBM 2997 cell separator.

, 1987
Takashi Shinozawa, Atsushi Shibuya, Sachie Otabe, Yōichi Ichikawa   +3 more
openalex   +2 more sources

Coagulation factors in spray‐dried plasma: A systematic review and meta‐analysis

Transfusion, EarlyView.
Biswadev Mitra, Patrick J. C. Biggins, Denese C. Marks, Michael C. Reade   +3 more
wiley   +1 more source

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

HemaSphere, Volume 9, Issue 4, April 2025.
Abstract Bispecific T‐cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL‐1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real‐world
Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman‐Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana von Metzler, Christian S. Michel, Carsten Müller‐Tidow, Sebastian Theurich, Karolin Trautmann‐Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab   +32 more
wiley   +1 more source

The distribution of HLA-A, B, C, Bf, C4 and two locus association of healthy apheresis donnor in Yamaguchi prefecture, western area of Japan.

, 1988
Hidenori Tanaka, Keiichi Itoh, K. Hirakawa   +2 more
openalex   +2 more sources

Safety of Apheresis Donation

Transfusion Medicine and Hemotherapy, 1987
Platelet and granulocyte collections have been done for the past 15 years, and studies on the safety of these procedures have been carried out in many institutions in the USA and abroad. In general, no long-term harmful effects have been observed in donors who had undergone frequent cytapheresis. Significant decreases in donor platelet count were noted
openaire   +3 more sources

Rare adverse reactions to therapeutic erythrocytes apheresis: a report of two cases

Zhongguo shuxue zazhi
Objective To investigate additional exclusion criteria for therapeutic apheresis erythrocytes and the possibility of adverse reactions by analyzing the occurrence of rare adverse reactions in two patients who underwent therapeutic erythrocytes apheresis.
Ling WU, Xinyu GAN, Qiang TAN, Li ZHANG, Tao PENG   +4 more
doaj   +1 more source

Effect of Plasma Apheresis (Selective LDL Adsorption Method) on the Levels of Plasma Lipids in a Familial Hypercholesterolemic (Homo IIa Type) Patient

, 1987
Noboru Yoshimine, Kanichi Asai, Fumio Kuzuya, Hirohisa Kawahara, T Suganuma, Takanobu Toriyama   +5 more
openalex   +2 more sources

SORBENTS/APHERESIS

, 1998
NULL AUTHOR_ID
openalex   +2 more sources

Evaluation of Albumin Loss During Low-density Lipoprotein Apheresis

, 1990
Shunichi Kojima, Mariko Shiba, Shuichi Nomura, Genjiro Kimura, Motoo Tsushima, Morio Kuramochi, Akira Yamamoto, Ttruo Omai   +7 more
openalex   +1 more source

Central Venous Access Device Complications and Premature Removal in Patients With Haematological Malignancies: A Multi‐Site Cohort Study

eJHaem, Volume 6, Issue 2, April 2025.
Abstract Background Patients with haematological malignancies require urgent and reliable venous access for the administration of systemic anticancer therapies (SACTs) commonly via central venous access devices (CVADs). Disease pathophysiology and side effects of SACTs increase the risk of complications during the dwell time and premature removal. CVAD
Kerrie Curtis, Samantha Keogh, Meinir Krishnasamy, Karla Gough   +3 more
wiley   +1 more source